← Eichor
Condition: Fgfr Gene Amplification Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Fgfr Gene Amplification

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Blad
Phase 2 · 46 location(s) · Tyra Biosciences, Inc · NCT06995677Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With
Phase 1 · 16 location(s) · Tyra Biosciences, Inc · NCT06915753Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
Phase 2 · 15 location(s) · Tyra Biosciences, Inc · NCT07265947
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.